Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Spark Therapeutics, a fully integrated company, strives to challenge the inevitabi...
Spark Therapeutics, a fully integrated company,...
United Therapeutics Corporation focuses on the strength of a balanced, value-creat...
United Therapeutics Corporation focuses on the ...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the de...
Kala Pharmaceuticals, Inc. (Kala) is a biopharm...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a world leader in developing allogene...
Mesoblast Limited (Nasdaq: MESO; ASX:MSB) is a ...
Eidos is a clinical stage biopharmaceutical company focused on addressing the larg...
Eidos is a clinical stage biopharmaceutical com...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.